Raphael Financial Statements From 2010 to 2025
| RAPH Stock | 1.00 0.00 0.00% |
Check Raphael Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Raphael Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Raphael financial statements analysis is a perfect complement when working with Raphael Pharmaceutical Valuation or Volatility modules.
Raphael |
Raphael Pharmaceutical OTC Stock Return On Asset Analysis
Raphael Pharmaceutical's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Raphael Pharmaceutical Return On Asset | -19.04 |
Most of Raphael Pharmaceutical's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Raphael Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Raphael Pharmaceutical has a Return On Asset of -19.0369. This is much lower than that of the sector and significantly lower than that of the Return On Asset industry. The return on asset for all United States stocks is notably higher than that of the company.
Raphael Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Raphael Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Raphael Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Raphael Pharmaceutical competition to find correlations between indicators driving Raphael Pharmaceutical's intrinsic value. More Info.Raphael Pharmaceutical is rated below average in return on asset category among its peers. It is rated below average in shares outstanding category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Raphael Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Raphael Pharmaceutical's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Raphael Pharmaceutical Financial Statements
Investors use fundamental indicators, such as Raphael Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Raphael Pharmaceutical's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Currently Active Assets on Macroaxis
Other Information on Investing in Raphael OTC Stock
Raphael Pharmaceutical financial ratios help investors to determine whether Raphael OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Raphael with respect to the benefits of owning Raphael Pharmaceutical security.